AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35856170 — intervention group
Group type: EXPERIMENTAL
Intervention: Program to Enhance Adjustment to Residential Living (PEARL)
Number of subjects: 219
Study 35856170 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 219
Study 32997386 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control)
Number of subjects: 992
Study 32997386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed for infants with DS
Number of subjects: 992
Study 32997386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed for older children with DS
Number of subjects: 992
Study 35599514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 84
Study 33300578 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Silexan
Number of subjects: 40
Study 33300578 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg Silexan
Number of subjects: 40
Study 33300578 — intervention group
Group type: COMPARATOR
Intervention: 2 mg lorazepam (active control)
Number of subjects: 40
Study 33300578 — intervention group
Group type: COMPARATOR
Intervention: 4 mg lorazepam (active control)
Number of subjects: 40
Study 33300578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32205026 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual action observation training (AAO) with rhythmic auditory stimulation and physical training
Number of subjects: 30
Study 32205026 — intervention group
Group type: COMPARATOR
Intervention: Visual action observation training (VAO) with physical training
Number of subjects: 30
Study 35318122 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz ON-tACS
Number of subjects: 85
Study 35318122 — intervention group
Group type: EXPERIMENTAL
Intervention: active ON-tDCS
Number of subjects: 85
Study 35318122 — intervention group
Group type: COMPARATOR
Intervention: sham ON-tDCS
Number of subjects: 85
Study 35318122 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz ON-tACS
Number of subjects: 85
Study 34736509 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Number of subjects: 0
Study 32063607 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme for patients with mild to moderate CTS
Number of subjects: 33
Study 32063607 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme for patients without CTS
Number of subjects: 33
Study 35369022 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 295
Study 35369022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 32845715 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (n=2419)
Number of subjects: 4822
Study 32845715 — intervention group
Group type: COMPARATOR
Intervention: valsartan (n=2403)
Number of subjects: 4822
Study 32845715 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4822
Study 32845715 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study 35080033 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus and Bifidobacterium lactis) for 10 weeks
Number of subjects: 32
Study 35080033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (potato starch)
Number of subjects: 32
Study 33555376 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical occlusion of the middle meningeal artery (soMMA) via a single burr hole during haematoma decompression
Number of subjects: 1162
Study 33555376 — intervention group
Group type: COMPARATOR
Intervention: Endovascular embolization of the middle meningeal artery (eMMA)
Number of subjects: 1162
Study 33827652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) programme
Number of subjects: 0
Study 33827652 — intervention group
Group type: COMPARATOR
Intervention: Normal social and emotional learning (SEL) school provision
Number of subjects: 0
Study 32822775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80
Study 32822775 — intervention group
Group type: COMPARATOR
Intervention: csDMARDs + GC
Number of subjects: 80
Study 33413508 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 71
Study 32045676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST) via videoconference
Number of subjects: 178
Study 32045676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 178
Study 32045676 — intervention group
Group type: COMPARATOR
Intervention: Pain Coping Skills Training (PCST) via in-person
Number of subjects: 178
Study 35513244 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib
Number of subjects: 354
Study 35513244 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 354
Study 35513244 — intervention group
Group type: COMPARATOR
Intervention: Validation set
Number of subjects: 354
Study 33960536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT)
Number of subjects: 96
Study 33960536 — intervention group
Group type: COMPARATOR
Intervention: Four Habits Model (FHM) with midazolam sedation
Number of subjects: 96
Study 35618742 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0
Study 35618742 — intervention group
Group type: COMPARATOR
Intervention: Autologous serum (AS)
Number of subjects: 0
Study 33735798 — intervention group
Group type: EXPERIMENTAL
Intervention: PA behavioural modification interventions alongside pulmonary rehabilitation (PR + PA)
Number of subjects: 48
Study 33735798 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone (PR)
Number of subjects: 48
Study 34995344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azacitidine (Oral‐AZA)
Number of subjects: 0
Study 34995344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33781435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month primary vaccination interval
Number of subjects: 21
Study 33781435 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 months primary vaccination interval
Number of subjects: 21
Study 33781435 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months primary vaccination interval
Number of subjects: 21
Study 32124014 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of massa intermedia (MI)
Number of subjects: 402
Study 33465455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724
Study 33465455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 34214454 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 107
Study 34214454 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 107
Study 32663278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (1 standard drink for women, 2 drinks for men)
Number of subjects: 26
Study 32663278 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (3 standard drinks for women, 4 drinks for men)
Number of subjects: 26
Study 32663278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 26
Study 32559607 — intervention group
Group type: COMPARATOR
Intervention: Published trials funded by NIH/US Federal Government
Number of subjects: 1389
Study 32559607 — intervention group
Group type: COMPARATOR
Intervention: Published trials funded by other non-industry organizations
Number of subjects: 1389
Study 32559607 — intervention group
Group type: COMPARATOR
Intervention: Published trials with procedural intervention
Number of subjects: 1389
Study 32559607 — intervention group
Group type: COMPARATOR
Intervention: Published trials with enrollment of >150
Number of subjects: 1389
Study 34774867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1.5 mA for 20 min)
Number of subjects: 56
Study 34774867 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS (1.5 mA for 20 min)
Number of subjects: 56
Study 34774867 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 56
Study 33307857 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (monitoring and data transmission twice per day, telephone call, and 2 home visits)
Number of subjects: 116
Study 33307857 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily visits)
Number of subjects: 116
Study 33307857 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 116
Study 33307857 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 33307857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 35211797 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3 days) with initial corticosteroid course
Number of subjects: 0
Study 35211797 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 32398420 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (300 mg fixed dose or dose-related based on total IgE level and body mass weight)
Number of subjects: 0
Study 32398420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 35084903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for CUD
Number of subjects: 302
Study 33285332 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (antagonist of muscarinic receptors)
Number of subjects: 0
Study 33285332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (antagonist of dopaminergic receptors)
Number of subjects: 0
Study 33285332 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (enhancing drug of cholinergic modulation)
Number of subjects: 0
Study 33285332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35795593 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Sodium Hyaluronate (SH)
Number of subjects: 30
Study 35795593 — intervention group
Group type: COMPARATOR
Intervention: Control (without SH)
Number of subjects: 30
Study 33395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg (oral and/or intravenous) once daily for 6 days
Number of subjects: 120
Study 33395210 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (selected by investigator from an allowed list) for 10 days
Number of subjects: 120
Study 33395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Number of subjects: 120
Study 33395210 — intervention group
Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 120
Study 34238836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing process software
Number of subjects: 80
Study 34238836 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital protocol
Number of subjects: 80
Study 32546177 — intervention group
Group type: EXPERIMENTAL
Intervention: ANtiPain intervention (face-to-face in-hospital session by a trained nurse and follow-up phone calls)
Number of subjects: 153
Study 32546177 — intervention group
Group type: EXPERIMENTAL
Intervention: ANtiPain intervention
Number of subjects: 153
Study 34261828 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Onyx zotarolimus‐eluting stent (RO‐ZES)
Number of subjects: 2488
Study 34261828 — intervention group
Group type: COMPARATOR
Intervention: Orsiro sirolimus‐eluting stent (O‐SES)
Number of subjects: 2488
Study 33275561 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported sleep patterns at age 2.5 yr
Number of subjects: 160
Study 33275561 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer settling times at age 2.5 yr
Number of subjects: 160
Study 33275561 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer settling times from ages 6 mo to 2.5 yr
Number of subjects: 160
Study 35609525 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (once a week for 6 weeks)
Number of subjects: 58
Study 35609525 — intervention group
Group type: COMPARATOR
Intervention: Control (routine maintenance of the chemotherapy unit)
Number of subjects: 58
Study 35609525 — intervention group
Group type: COMPARATOR
Intervention: Reflexology and Control
Number of subjects: 58
Study 33813855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension label
Number of subjects: 1318
Study 33813855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal BP label
Number of subjects: 1318
Study 33813855 — intervention group
Group type: COMPARATOR
Intervention: Control (general BP description)
Number of subjects: 1318
Study 33813855 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing absolute risk information in the hypertension group
Number of subjects: 1318
Study 33095779 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 cut-off score for people with type 2 diabetes
Number of subjects: 315
Study 33095779 — intervention group
Group type: COMPARATOR
Intervention: PHQ-9 cut-off score for people without diabetes
Number of subjects: 315
Study 33095779 — intervention group
Group type: COMPARATOR
Intervention: Two-stage method for people without diabetes
Number of subjects: 315
Study 36204969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silymarin-loaded antioxidant serum (SAS) applied twice daily for 4 weeks
Number of subjects: 22
Study 36204969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silymarin-loaded antioxidant serum (SAS)
Number of subjects: 22
Study 36204969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silymarin-loaded antioxidant serum (SAS) with low-dose oral isotretinoin
Number of subjects: 22
Study 33260141 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (0.09 g/kg providing 3 mg/kg of caffeine)
Number of subjects: 46
Study 33260141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 32933954 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related behavioural activation (F-BA) therapy
Number of subjects: 1025
Study 32933954 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplements
Number of subjects: 1025
Study 32933954 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 1025
Study 32933954 — intervention group
Group type: COMPARATOR
Intervention: No behavioural intervention
Number of subjects: 1025
Study 33471625 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/d of milk protein concentrate
Number of subjects: 25
Study 33471625 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate placebo
Number of subjects: 25
Study 32435005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost eye drop (0.015%) applied to one eye (miosis group)
Number of subjects: 0
Study 32435005 — intervention group
Group type: COMPARATOR
Intervention: No treatment (mydriasis group)
Number of subjects: 0
Study 35088499 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (systemic immunosuppressant, antihistamine, calcium gluconate, topical salicylic acid)
Number of subjects: 132
Study 35088499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus supplemental essential phospholipids (EPL)
Number of subjects: 132
Study 34290085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (20 mL of adrenalized levobupivacaine 0.50%)
Number of subjects: 40
Study 34290085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Number of subjects: 40
Study 34290085 — intervention group
Group type: COMPARATOR
Intervention: Suprainguinal fascia iliaca block (40 mL of adrenalized levobupivacaine 0.25%)
Number of subjects: 40
Study 36118104 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing the Serola Sacroiliac Belt during a 10-minute daily repeated strenuous lifting task
Number of subjects: 33
Study 36118104 — intervention group
Group type: COMPARATOR
Intervention: Not wearing the Serola Sacroiliac Belt during the same lifting task
Number of subjects: 33
Study 36118104 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing the Serola Sacroiliac Belt
Number of subjects: 33
Study 36118104 — intervention group
Group type: COMPARATOR
Intervention: Not wearing the Serola Sacroiliac Belt
Number of subjects: 33
Study 32586259 — intervention group
Group type: EXPERIMENTAL
Intervention: QSPR models using backward‐multiple linear regression (MLR) and genetic algorithm (GA‐MLR) for descriptor selection
Number of subjects: 91
Study 32586259 — intervention group
Group type: EXPERIMENTAL
Intervention: QSPR models with five descriptors in three blocks: connectivity, edge adjacency indices, and 2D matrix‐based descriptors
Number of subjects: 91
Study 32896349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography for assessing costal cartilage calcification
Number of subjects: 65
Study 32896349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography for assessing honeycombed phenomenon
Number of subjects: 65
Study 34845507 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant prophylaxis (not specified dosage or duration)
Number of subjects: 0
Study 34845507 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for signs of VTE after laparoscopic surgery
Number of subjects: 0
Study 33619809 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric sonic device
Number of subjects: 12
Study 33619809 — intervention group
Group type: COMPARATOR
Intervention: Manual cleansing
Number of subjects: 12
Study 36480569 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive & Thrive's IYCF social and behavior change communication intervention
Number of subjects: 6326
Study 36480569 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6326
Study 34633753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg twice daily)
Number of subjects: 259
Study 34633753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 32678852 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (CNP)
Number of subjects: 4846
Study 32678852 — intervention group
Group type: COMPARATOR
Intervention: Physical activity intervention (PA)
Number of subjects: 4846
Study 32678852 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education intervention (NE)
Number of subjects: 4846
Study 35879756 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition (AI) technique with Conventional therapy
Number of subjects: 80
Study 35879756 — intervention group
Group type: COMPARATOR
Intervention: Reciprocal Inhibition (RI) technique with Conventional therapy
Number of subjects: 80
Study 33524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Philadelphia cervical collar
Number of subjects: 2
Study 33524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Miami‐J cervical collar
Number of subjects: 2
Study 32822827 — intervention group
Group type: EXPERIMENTAL
Intervention: asthma education + home environment remediation + school intervention
Number of subjects: 300
Study 32822827 — intervention group
Group type: EXPERIMENTAL
Intervention: asthma education + home environment remediation
Number of subjects: 300
Study 32822827 — intervention group
Group type: COMPARATOR
Intervention: comparator condition
Number of subjects: 300
Study 36326931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery Group (SG)
Number of subjects: 30
Study 36326931 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy Group (EG)
Number of subjects: 30
Study 35092016 — intervention group
Group type: EXPERIMENTAL
Intervention: Program for the Education in Enrichment of Relational Skills (PEERS)
Number of subjects: 36
Study 35092016 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 34708460 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg daily)
Number of subjects: 124
Study 34708460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 34708460 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 124
Study 33782836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampreloxetine (10 mg once daily)
Number of subjects: 34
Study 32068002 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide 4 mg once daily for 28 days
Number of subjects: 71
Study 32068002 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide 40 mg once daily for 28 days
Number of subjects: 71
Study 32068002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 32631173 — intervention group
Group type: EXPERIMENTAL
Intervention: OPD structural integration
Number of subjects: 719
Study 33668937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (PLY)
Number of subjects: 17
Study 33668937 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 17
Study 37885327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation program (twice a week for 4 weeks via video conference)
Number of subjects: 59
Study 37885327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 34291443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1g IV at surgery initiation and 500mg orally every 8 hours for 3 days)
Number of subjects: 108
Study 34291443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 108
Study 34291443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 108
Study 32219526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) steroids
Number of subjects: 0
Study 32219526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) gentamicin
Number of subjects: 0
Study 32219526 — intervention group
Group type: COMPARATOR
Intervention: Control group (IT steroids)
Number of subjects: 0
Study 33397664 — intervention group
Group type: EXPERIMENTAL
Intervention: App Tät (3 months use)
Number of subjects: 2672
Study 33397664 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted results to match RCT severity distribution
Number of subjects: 2672
Study 33397664 — intervention group
Group type: COMPARATOR
Intervention: RCT
Number of subjects: 2672
Study 32945774 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat users
Number of subjects: 400
Study 32945774 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based mHealth program endorsement
Number of subjects: 400
Study 35927645 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cages
Number of subjects: 104